11/11/2011 8:04:11 AM
PHILADELPHIA--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced results from additional analyses of the EMERALD Phase 3 studies that evaluated the investigational agent peginesatide in dialysis patients with anemia due to chronic kidney disease (CKD). The findings, presented at the American Society of Nephrology’s (ASN) Kidney Week, provide further detail on the frequency of adverse events of peginesatide and epoetin alfa or beta, as well as information on the relationship between peginesatide and epoetin doses in the dialysis patients studied, dose requirements of intravenous (IV) and subcutaneous (SC) peginesatide in patients in the United States (US) and European Union (EU) and hemoglobin (Hb) stability. The companies also presented findings on the rate of Hb decline associated with peginesatide and epoetin following dose discontinuation seen in these studies.
comments powered by